CDC recommends new booster shots to fight omicron
CDC Director Rochelle Walensky has signed off on updated versions of the Moderna and Pfizer-BioNTech vaccines that target the original virus and the omicron subvariants.
pfizer
FDA authorizes first revamp of COVID vaccines to target omicron
The new shots from Moderna and Pfizer-BioNTech target both the original strain of the coronavirus and the omicron BA.4/BA.5 subvariants that most people are catching now.
Moderna sues Pfizer over COVID-19 vaccine patents
The vaccine maker alleges that its rivals Pfizer and BioNTech used some patented features of its mRNA technology to develop their COVID vaccines.
Pfizer asks FDA to greenlight new omicron booster shots, which could arrive this fall
Pfizer has submitted data on its bivalent COVID-19 booster shot that specifically targets the latest omicron subvariants. If authorized, the company says the shots could be ready as soon as September.
Advisers to the FDA back COVID vaccines for the youngest children
A committee of experts voted unanimously to recommend that the Food and Drug Administration authorize COVID-19 vaccines from Moderna and Pfizer-BioNTech for children as young as 6-months-old.
Pfizer asks FDA to authorize booster shots for kids ages 5 through 11
Data show that a third dose can help boost kids' immunity. Some experts are skeptical that another shot is needed for younger kids.
Moderna says its new 'bivalent' vaccine shows promise against COVID variants
The company says this version targets both the original coronavirus and the beta variant, and appears to provide broader and longer-lasting protection against different strains, including omicron.
Pfizer-BioNTech will seek authorization for second COVID booster for older adults
Pfizer and BioNTech are planning to ask the Food and Drug Administration to authorize a second COVID-19 booster shot for people age 65 and older.
The FDA postpones a highly anticipated meeting on the Pfizer vaccine for young kids
"We believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization," FDA officials said in a statement.
Feds' contract with Pfizer for Paxlovid has some surprises
NPR has obtained the government's $5.3 billion contract for the first 10 million courses of Paxlovid, an antiviral pill for COVID-19. Here's what's in it.